Arcutis Biotherapeutics Q2 2024 GAAP EPS $(0.42) Beats $(0.51) Estimate, Sales $30.86M Beat $27.73M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arcutis Biotherapeutics (NASDAQ:ARQT) reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.42), beating the estimate of $(0.51). Sales also surpassed expectations, reaching $30.86 million compared to the $27.73 million estimate. This marks a significant improvement from the same period last year.
August 14, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcutis Biotherapeutics reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.42) and sales of $30.86 million, both beating analyst estimates. This represents a significant improvement from the same period last year.
The company's better-than-expected earnings and sales figures, along with significant year-over-year improvements, are likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100